



Herausforderung Mikroschadstoffe


Praktische Beiträge der Nachhaltigen Pharmazie



Prof. Dr. Klaus Kümmerer
Klaus.Kuemmerer@uni.leuphana.de




Elimination of Micro-Pollutants in Advanced Waste Water Treatment



J. Margot et al. (2011), Poster SETAC



UV-Photolysis of Ciprofloxacin (Mediated by •OH-Radicals)




▣ 362.4(3.3) ▣ 362.4(4.4) □ 316.8(6.1) □ 330.3(6.3) □ 346.2(7.5) ■ 332.2(8.0) □ 344.7(11.3) □ 316.3(11.7) □ 330.3(12.3)

BOOK Haddad and Kümmerer, Chemosphere (2015) 115, 40-46



UV-Photolysis of Ciprofloxacin (Genotoxicity of Transformation Products)



☒ Garcia-Käufer M, Haddad T, Gupta P, Gminski R, Kümmerer K, Mersch-Sundermann V, ESPR (2012) 19, 1719-1727




© Prof. Dr. Klaus Kümmerer



Products of Incomplete Mineralization

(Advanced Effluent Treatment, reported until 2012)



✉ Haddad T, Baginska E, Kümmeler K; Water Research, 2015



Wir stoßen zunehmend an Grenzen!

1. Jedes Verfahren entfernt nur eine jeweils spezifische Minderheit von Substanzen
 2. Bei oxidativen Verfahren wird eine Vielzahl von Abbauprodukten mit unbekannten Eigenschaften und Toxizität gebildet
 3. Die Stoffe der Zukunft kennen wir nicht
-
4. Ca. 35 000 Stoffe relevant, pro Stoff 5 Abbauprodukte? welche und wieviele Toxizitätsendpunkte mit welchem Test?



Measures at the Source

Member States **should tackle the sources of pollution** ... This is **much preferable to using end-of-pipe treatment** ... while avoiding high treatment costs and protecting the environment.

9.3.2015



COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL
The Water Framework Directive and the Floods Directive: Actions towards the 'good status' of EU water
and to reduce flood risks /* COM/2015/0120 final */., 9.3.2015



Eintragsreduktion durch Information und Ausbildung

Information Bevölkerung
Patient-Arzt-Interaktion
Ärztefortbildung
Ärzteausbildung

Haben Sie Fragen?
Sprechen Sie uns an.

Abfallwirtschaft und
Stadtentwicklung Freiburg GmbH
Hermannstraße 10
79108 Freiburg
Telefon 07 61 67 00 40
www.abfallwirtschaft-freiburg.de

Abwasserzweckverband
Bregenzer Ach
Hermannstraße 10
79108 Freiburg
Telefon 07 61 52 17 40
www.abwasser-zvg.de

Landesärztekammer
Baden-Württemberg
Ausschuss Prävention und Umwelt
Jahresstraße 40
70297 Stuttgart
Telefon 07 11 76 98 90
www.rae.kam-bw.de

Landesgeoherkerverband
Baden-Württemberg e.V.
Hohenloher Straße 12
70174 Stuttgart
Telefon 07 11 21 34 77
www.agk-bw.de

Stadtwerke Freiburg I. Br.
Eigenbetrieb der Stadt Freiburg I. Br.
Sandgrube 1
79114 Freiburg
Telefon 07 61 21 44 01
www.wasser-freiburg.de

Universitätsklinikum Freiburg
Institut für Medizinische und
Krankenhygiene
Breisacher Straße 115 B
79110 Freiburg
Telefon 07 61 70 82 36
www.uk-freiburg.de

In Zusammenarbeit
mit dem Institut für
Umweltmedizin der
Krankenhaus am Kaiserin,
Sektion Angewandte
Umweltmedizin
Universitätsklinikum
Freiburg

badenova

Arzneimittel –
Wasser – Umwelt
So schützen wir vorsorglich
unser Trinkwasser



Innovative Konzepte und Technologien für die separate Behandlung
von Abwasser aus Einrichtungen des Gesundheitswesens

SAUBER+

Umwelt
Bundesamt

Institut für
sozial-ökologische
Forschung

start
Strategien zum Umgang mit
Arzneimittelwirkstoffen
im Trinkwasser

Bundesministerium
für Bildung
und Forschung

© Prof. Dr. Klaus Kümmerer

LEUPHANA
Institut für Biochemie
Chemie und Umweltchemie

Meeting the Hygienical Standard



schülke -




© Prof. Dr. Klaus Kümmerer



De-Novo Design - Targeted Synthesis

New Lead Structure by Ligand Variation



Efficacy and biodegradability in the environment:

- Improved by variation of the sugar?
- Improved by variation of substituents at the furan ring?
- Improved by variation of the aromatic ring?

✉ Kümmerer K, Frei E, Marano G, in preparation







© Prof. Dr. Klaus Kümmerer




Targeted Structure Variation

✉ Kümmerer K, Frei E, Marano G, in preparation



Structure ID	Log Kow	Effect threshold (rel. units)	Biodegradation[%]
GSF	-2.1	1	19
2211_2 (Glu , Cyclohex)	-1.8	> 1	37
2211_3 (Gal, Cyclohex)	-1.8	> 1	37
2211_4 (Glu-Br)	-0.5	> 1	14
2211_5 (Glu-F)	-0.9	> 1	14
2211_6 (Glu-Cl)	-0.7	> 1	14
2211_7 (Glu-I)	-0.5	> 1	14
2211_8	-2.0	<0,01	54
2211_9 (Desoxyglu)	-1.5	> 1	31



✉ Frei et al., patent pending




Re-Design



✉ Rastogi T, Leder C, Kümmeler K (2015), ES&T, 49, 11756–11763 (open access)



Non-targeted Generation of Derivatives of Propranolol




Rastogi T, Leder C, Kümmerer K (2015), ES&T, 49, 11756–11763 (open access)



© Prof. Dr. Klaus Kümmerer




Methods




Rastogi T, Leder C, Kümmerer K (2015), ES&T, 49, 11756–11763 (open access)



Docking



Docking Score:
- 9.1



Docking Score:
- 9.3

✉ Rastogi T, Leder C, Kümmeler K (2015), ES&T, 49, 11756–11763 (open access)



© Prof. Dr. Klaus Kümmeler



LEUPHANA
Institut für Bioökologie und
Chemie der Umweltchemie

Toxicity Assessment 4-Hydroxypropranolol

(In Silico Prediction)

QSAR Software	Models	End points	Propranolol	4-OH Propranolol
CASE Ultra v. 1.5.2.0 (as per ICH M7 guidelines)	Salmonella mutagenicity	Mutagenicity	Known negative	Negative
	A-T site mutation	Mutagenicity	Inconclusive	Negative
	Expert rules for genotoxicity	Genotoxicity	Known negative	Positive
	E.coli mutagenicity	Mutagenicity	Negative	Negative
	Salmonella mutagenicity	Mutagenicity	Known negative	Negative
Leadscape Model Applier Version: 1.8.6 (as per ICH M7 guidelines)	ICH M7 Genetox Consensus	Genetox Consensus	Negative	Negative
	E Coli - Sal 102 A-T mutagenicity	Mutagenicity	Negative	Negative
	Salmonella mutagenicity	Mutagenicity	Negative	Negative
	Bacterial Mutation	Mutagenicity	Negative	Negative
	Human carcinogenicity	Carcinogenicity	Negative	Negative
CASE Ultra v.1.4.5.1	Micronucleus formation in vivo composite	Genotoxicity	Positive	Negative
	Chromosome aberration in vitro composite	Mutagenicity	Marginal positive	Negative
OASIS Catalogic	In vitro Ames model	Mutagenicity	Negative	Negative




ADME Properties of 4-Hydroxypropranolol

(In Silico Prediction)

ADME properties	Description	Range or recommended values	Atenolol	Metoprolol	Propranolol	4-Hydroxy propranolol
Rule of 5	Lipinski's rule of five.	Fewer or no violations	0	0	0	0
Rule of 3	Jorgensen's rule of three.	Fewer or no violations	0	0	0	0
$\log P_{o/w}$	Octanol/water partition coefficient.	-2.0 to 6.5	0.17	1.9	3.1	2.1
$\log S$	Aqueous solubility	-6.5 to 0.5	-1.3	-1.4	-3.5	-2.1
$\log \text{IC}_{50}$	IC ₅₀ value for blockage of HERG K ⁺ channels.	Concern below -5	-4.5	-6.1	-5.9	-5.9
P Caco	Apparent Caco-2 cell permeability	<25 poor and >500 great	33.9	733.9	1147.9	320.7
log BB	Brain/blood partition coefficient	-3.0 to 1.2	-1.21	-0.22	0.22	-0.4
P MDCK	Apparent MDCK cell permeability	<25 poor and >500 great	32.0	391.7	635.3	160.1
$\log K_p$	Skin permeability	-8.0 to -1.0	-5.2	-3.2	-2.6	-3.7
Human-oral absorption		1, 2, or 3 for low, medium or high, respectively	2	3	3	3
$\log K_{hsa}$	Binding to human serum albumin	-1.5 to 1.5	-0.76	-0.15	0.05	-0.12
CNS	Central nervous system activity	-2 (inactive) to 2 (active)	1	-2	1	0



Pharmacological Activity of 4-Hydroxypropranolol (In Vitro Analysis)




📖 Rastogi T, Leder C, Kümmeler K (2015), ES&T, 49, 11756–11763 (open access)



4-Hydroxypropranolol


Pharmaceutically
active and
environmentally
biodegradable photo
transformation product
Including metabolite



✉ Rastogi T, Leder C, Kümmeler K (2015), ES&T, 49, 11756–11763 (open access)



Re-Design



- 📖 Rastogi T, Leder C, Kümmerer K (2014), Chemosphere, 111, 493–499 (Metoprolol)
- 📖 Rastogi T, Leder C, Kümmerer K (2015), RSC Advances, RSC Advances, 5, 27-32 (Atenolol)
- 📖 Rastogi T, Leder C, Kümmerer K (2015), ES&T, 49, 11756–11763 (Propranolol; open access)



© Prof. Dr. Klaus Kümmerer



Zusammenfassung

1. (Erweiterte) Abwasserreinigung kann die Probleme nicht lösen
2. Information und Ausbildung kann zur Reduktion beitragen
3. Re-Design kann zu umweltverträglichen Wirkstoffen führen
4. Umweltverträglichkeit kann bei neuen Wirkstoffen gezielt eingebaut werden

